Search

Diffuse midline glioma is a devastating brain tumour, affecting primarily young children. There’s currently no cure for this disease and treatment options are limited. This is mainly because this type of tumour is well-protected from drugs by the ‘blood-brain barrier’. This barrier physically blocks all medications from entering the brain. Our group has developed new methods of bypassing this barrier using focused ultrasound.

Finding a way to use immunotherapy against a high-risk type of childhood brain tumour.

Identifying markers that can be used for a non-invasive test to diagnose and monitor Wilms tumour.

Looking at cancer samples to find markers that can predict how a child's cancer will respond to treatment.

Developing and delivering small molecule drug and immunotherapy combinations for MYC-driven medulloblastoma: Efficacy, evolution and exploitation.

Your child will usually need to spend some time in hospital during their treatment. All children and young people diagnosed with cancer are treated in one of the 21 specialist hospital centres across the UK and Ireland.

Single-cell transcriptomics linked to lineage tracing to interrogate the role of intra-tumour heterogeneity in shaping therapeutic susceptibility and resistance in paediatric cancer

Development of a multi-factorial prognostic model to optimise treatment decision making and outcomes in paediatric low-grade glioma

Defining the molecular landscape of paediatric and adolescent acute leukaemia in Tanzania

Optimising tyrosine kinase inhibitor therapy in newly diagnosed metastatic Ewing sarcoma